Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
141 words
A composition suitable for topical or subcutaneous application to a human for the treatment of cancerous or virus-caused skin disorders consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), and a fibronectin or large external transformation sensitive protein (LETS) selected from the group of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 2
Dependent Claim
141 words
A composition suitable for topical or subcutaneous application to a human for the treatment of cancerous or virus-caused skin disorders consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen activator (t-PA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), and a fibronectin or large external transformation sensitive protein (LETS) selected from the group of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG) and opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 3
Dependent Claim
14 words
A composition in accordance with claim 1 wherein said human interferon is human alpha-interferon.
Claim 4
Dependent Claim
15 words
A composition in accordance with claim 1 wherein said antiviral surfactant is a nonionic surfactant.
Claim 5
Dependent Claim
14 words
A composition in accordance with claim 1 wherein said antiviral surfactant is nonylphenoxypolyethoxy ethanol.
Claim 6
Dependent Claim
12 words
A composition in accordance with claim 1 wherein said adjuvant is dimethylsulfoxide.
Claim 7
Dependent Claim
13 words
A composition in accordance with claim 1 wherein said adjuvant is a glycol.
Claim 8
Dependent Claim
30 words
A composition in accordance with claim 1 wherein said composition additionally contains an antitumor agent selected from the group consisting of a lymphotoxin, tumor necrosis factor (TNF) and an interleukin.
Claim 9
Dependent Claim
14 words
A composition in accordance with claim 1 wherein said carrier is an aqueous gel.
Claim 10
Dependent Claim
38 words
A composition in accordance with claim 1 wherein said carrier is an aqueous gel and wherein said antiviral surfactant is present in an amount in the range from about 0.1 to about 20% by weight of said composition.
Claim 11
Independent Claim
140 words
A method for treating cancerous or virus-caused skin disorders of a human which comprises topically or subcutaneously applying a composition consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen (tPA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF) granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) selected from the group consisting of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG), opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 12
Independent Claim
140 words
A method for treating cancerous or virus-caused skin disorders of a human which comprises topically or subcutaneously applying a composition consisting essentially of a physiologically acceptable carrier, an antiviral or anti-cancer effective amount of a biologically active material selected from the group consisting of tissue plasminogen (tPA), epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), human endothelial cell growth factor (ECGF) granulocyte macrophage colony stimulating factor (GM-CSF) and a fibronectin or large external transformation sensitive protein (LETS) selected from the group consisting of cell surface protein (CSP), cell adhesion protein (CAP), cell insoluble globulin (CIG), opsonic-alpha 2 surface binding protein, an effective antiviral amount of an antiviral surfactant, an effective antiviral amount of human interferon and an effective amount of an adjuvant to assist in the transdermal transport or transfer of said composition through the skin.
Claim 13
Dependent Claim
31 words
A method in accordance with claim 10 wherein said applied composition additionally contains an anti-tumor agent selected from the group consisting of a lymphotoxin, tumor necrosis factor (TNF) and an interleukin.
Claim 14
Dependent Claim
73 words
A method in accordance with claim 10 wherein said physiologically acceptable carrier comprises an aqueous gel, wherein said antiviral surfactant is a nonionic surfactant, wherein said human interferon is human alpha interferon, wherein said adjuvant is selected from the group consisting of dimethylsulfoxide and a glycol and wherein said composition additionally includes an effective amount of an anti-tumor agent selected from the group consisting a lymphotoxin, tumor necrosis factor (TNF) and an interleukin.